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AbsTRACT
Recently there have been reports of osteonecrosis of the jaw (ONJ) in patients with chronic therapy with bisphosphonates 
(Bps). So far three drugs have been linked: Pamidronate of disodium, Zoledronic acid and Alendronate of sodium. It is 
due to a non detected side effect in clinical trials before commercialization, and reverberates significantly in the quality 
of life of these patients.
Most of the cases are seen in oncology patients that have received long term concurrent antineoplasic therapy and were 
treated sporadically with steroids, together with Bps endovenous, for treatment of cancer and its symptoms. Among 
these cases we find the reported by R.E. Marx (1), S.L. Ruggiero (2) and J. V. Bagán (3).
In this report fifteen cases diagnosed, treated and followed up at the author´s surgery department are presented and some 
suggestions are given in order to reduce the incidence in patients with cancer who are going to receive Bps, as well as in 
patients with established ONJ being treated with these drugs who may need a surgical intervention.
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REsUMEN
Recientemente se han descrito casos de osteonecrosis mandibular y maxilar (ONM) en pacientes sometidos a tratamiento 
crónico con bisfosfonatos (BF). Hasta el momento tres han sido los fármacos implicados: Pamidronato de disodio, Ácido 
Zoledrónico  y Alendronato de sodio. Se trata de un efecto secundario muy poco frecuente, no detectado en ensayos 
clínicos precomercialización, que repercute de forma significativa en la calidad de vida de estos pacientes.
La mayoría de los casos se dan en pacientes oncológicos que reciben tratamiento antineoplásico concomitante a largo 
plazo y muchos de ellos estaban sometidos a tratamiento intermitente con esteroides a corto plazo, junto a los bisfosfonatos 
vía endovenosa, para el tratamiento del cáncer y de los síntomas. Entre estos casos se encuentran los publicados por 
R.E. Marx (1), S.L. Ruggiero (2) y J. V. Bagán (3).
Este artículo presenta  quince casos clínicos diagnosticados, tratados y seguidos por nuestro servicio y da una serie de 
recomendaciones para reducir su incidencia en pacientes con cáncer que van a recibir  BF, así como en pacientes con 
ONM establecida en tratamiento con dichos fármacos y que puedan necesitar un tratamiento quirúrgico.
Palabras clave: Bisfosfonatos, osteonecrosis maxilar, recomendaciones.
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bACKGROUND
ONJ induced by Bps appears as a side effect. Most of the 
cases are seen in oncology patients that, besides intravenous 
Bps, have received chemotherapy in the long term for their 
base disease with or without intermittent cycles of steroids 
(3-5). Its incidence remains unknown in patients with cancer 
although current estimations suggest that it is low, daily more 
cases are being detected so it is expected that this tendency 
will increase (has been called “growing epidemic” (4,6,7)). Its 
appearance has been associated with various risk factors like 
cancer diagnosis, concurrent treatments (systemic chemothe-
rapy, radiotherapy of head and neck or steroids) and medical 
comorbidities (anaemia, coagulation disorders, infection, 
dental disease comorbidity). ONJ has also been observed 
though less often in patients receiving less powerful Bps for 
management of osteoporosis during a long period of time. 
It is not clear its time-dependency, Brian et al. (8), found in 
a evaluation of 812 patients with multiple myeloma in treat-
ment with Bps that the risk of osteonecrosis is significant 
after 12 months (p=0.03), with a further increase after 36 
months (p=0.004). On the other hand, cases exist in patients 
that have used the drugs for only a few weeks. (9).
Mechanism of action begins to be recognized, these drugs 
are analogues of pyrophosphate and present high affinity 
to hidroxiapatita crystals and inhibit bone resorption. They 
inhibit osteoclastes activity too and therefore decrease bone 
remodelling.
CLINICAL CAsEs
A retrospective study of 15 cases of ONJ in patients recei-
ving Bps was performed in our department from October 
2005 to February 2006 (Table 1). 
Patient Sex Age Diagnosis Bisfosfonate Localization Treatment 








2 F 75 Osteoporosis. Alendronate. Mandible. Clean and sequestrectomy. 
3 M 62 Multiple Myeloma. Zoledronic Acid. Mandible. Bone contouring. 







and EIMF . 
5 M 66 Prostate Ca. Vertebral Mts. Zoledronic Acid. Mandible. Curettage. 
6 F 59 Breast Ca. Bone and lung Mts. Zoledronic Acid. 
Mandible and 
maxillary. 
7 F 72 Breast Ca. Zoledronic Acid. Maxillary Sinusitis. 
Segmentary 
Maxilectomy, 
cleaning of sinus, 
drainage and bone 
contouring. 
8 F 41 
Breast Ca. 
Vertebral and liver 
Mts. 
Zoledronic Acid. Mandible and  maxillary. 
9 M 61 Multiple Myeloma. Zoledronic Acid. Mandible.  
10 F 63 Multiple Myeloma. Zoledronic Acid and Pamidronate. Maxillary. 
Remodelation of 
exposed bone and 
closure.
11 F 60 Breast Ca. Zoledronic Acid. Mandible. Remodelation of exposed bone. 
12 M 69 Prostate Ca. Zoledronic Acid. Mandíble.  
13 M 70 Prostate Ca. Zoledronic Acid. Mandible.  
14 F 73 Osteoporosis. Alendronate. Mandible.  
15 F 68 Multiple Myeloma. Zoledronic Acid. Mandible.  
Table 1. Relation of clinical cases.
* In all patients the first treatment was conservative (antibiotic therapy and mouth rinses of gluconate of clorohexidi-
ne). Ca.= Carcinoma. Mts.= Metastase. F.= Female. M.= Male. D-L.= Dorso-lumbar. EIMF.= Elastic Intermaxillary 
Fixation.
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Most of the study took place in oncology patients receiving 
antineoplasic therapy, often in addition to intermittent 
cycles of steroids. A total of 10 women (66.6%) and 5 men 
(33.3%) were included in this report with an average age of 
64 years (41-75). Both, multiple myeloma and breast cancer 
were the most common indication for BP with 5 cases (33.3% 
every one), followed by 3 cases for prostate cancer (20%) and 
2 cases for osteoporosis (13.3%). Bp administrated was zo-
ledronic acid (Zometa®) in 13 cases, alendronate of sodium 
(Fosamax®) oral route in 2 cases (13.3%), and pamidronate 
of disodium (Aredia®) in addition to zoledronic acid only 
in one case. Tooth removal was found in 6 cases (40%). The 
most common site of bone exposure was the mandible with 
13 cases (86.6%), 3 of them had involved the maxillary bone 
(20%). Only 2 patients were affected in the maxillary bone 
exclusively. 14 patients presented with exposed bone in the 
oral cavity (93.3%), the only patient that didn’t, presented 
a gingival granuloma in the 48 (6.7%) and paresthesia in 
dental nerve territory. 3 patients (20%) presented with 
anesthesia, disesthesia, hipoesthesia or paresthesia. 3 cases 
of cutaneous fistula (20%), 2 of oro-antral communication 
and maxillary sinusitis associated (13.3%) and 1 pathologic 
fracture of mandible were seen (6.6) (figure 1). Biopsy was 
performed on 9 patients (60%): the result was non specific 
inflammation in 3 cases and osteomyelitis in 6, in 5 of them 
Actinomyces could be detected.
A conservative attitude was supported for initial stage of 
treatment (intermittent-continous cycles of systemic anti-
biotic therapy and mouth rinsing with 0.12% gluconate of 
clorohexidine), resulting successfully in 7 cases (46.6%). 
Besides exposed bone ulcerating soft tissues (33,3%) was 
remodelled in 5 cases. Among 2 patients with oro-antral 
communication and maxillary sinusitis associated: the first 
one presented a basal condition that advised cleaning of the 
maxillary sinus, bone contouring and covering the exposed 
bone with mucous flap; on the second one segmentary 
maxillectomy, extirpation of mucosa of the maxillary sinus, 
drainage, contouring bone and closure with mucous flap was 
performed without new exposed-bone appearance. The only 
patient without exposed bone had a gingival granuloma in 
48 and evolved satisfactorily after curettage, local debri-
dement and closure with mucous flap. Finally, in 2 cases 
with chronic suppuration and cutaneous fistula by ONJ 
in the third quadrant (13.3%)  marginal mandibulectomy, 
preserving mandibular basal in the first one and contouring 
bone in the second one, followed by closure with mucous 
flap and fistulectomy in both of them was performed. The 
first one evolved successfully and the second one developed 
a pathologic fracture of mandible few months later, treated 
by radical resection of necrotic bone (figure2) and elastic 
intermaxillary fixation in order to organize a bone recons-
truction, in the short term.
DIsCUssION
Although controlled, randomized, prospective, double 
blinded study with p<0.05% would be necessary to prove 
the specific causal relationship between Bps therapy and 
Fig. 3. Maxillary sinusitis.
Fig. 1. Pathologic fracture of mandible.
Fig. 2. Segmentary resection of mandible.
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exposed bone, many times painful in oral cavity, the drugs 
pamidronate, zoledronic acid and alendronate have shown 
a direct correlation that cannot be ignored.
Bps are inhibitors of osteoclastic bone resorption with high 
affinity for bone mineral and are used in the treatment of 
skeletal disorders like osteoporosis, Paget´s disease, bone 
metastasic disease, multiple myeloma and hypercalcemy in 
metastasic cancer. The molecular mechanism of action de-
pends on the presence of a nitrogen atom in the alkyl chain 
of the molecule. Non–nitrogen-containing Bps (nNBps) are 
converted intracellulary to nonhydrolyzable analogues of 
ATP, which are toxic for the cells. Nitrogen-containing Bps 
(NBps), however, are taken up by mature osteoclasts losing 
their cytoeskeletal integrity and shape, become inactive 
and undergo apoptosis. Although there are studies that 
demostrate antiangiogenic effect of Bps like pamidronate 
and zoledronic acid, it doesn´t seem to be responsible for 
the production of ONJ.
This mechanism of action justifies their properties: helping 
to control bone pain, stabilizing litics bone metastase and 
preventing its appearance, reducing incidence of pathologic 
fractures, malignant hypercalcemy and need for palliative 
radiotherapy, improving quality of life of these patients. 
Delay the first skeletal complication and the need for or-
thopaedic intervention due to skeletal pathology, but they 
do not improve the patient´s survival (10, 11).
However, if  Bps are used for the management and preven-
tion of skeletal events, why is there an association between, 
Bps therapy and ONJ?, may be attributable to the fact that 
the bones of the jaws have a faster bone turnover (12) and 
to the fact that they are in direct contact with a septic en-
vironment (bacterial products have been shown to increase 
bone resorption and to decrease bone formation (13)). It 
is a strange and contradictory fact of which more research 
would be needed.
ONJ can remain asymptomatic for weeks or months and be 
recognized only by the presence of exposed bone in oral cavi-
ty, sometimes painless. As soon as the oncologist prescribes 
Bps therapy, the patient should be referred to a dentist or 
oral and maxillofacial surgeon for a complete examination 
of the oral cavity (1, 14) that includes an orthopantograph 
in every case and dental radiograph of the necessary teeth. 
In the orthopantograph it is frequent to find zones of os-
teolysis, sometimes in combination with osteosclerosis as 
well as periodontal disturbances (it is characteristic bone 
loss between the roots of the third molar).
Biopsy is only indicated if  you suspect bone metastasis in 
the manbible or the maxillary. If  you perform it, micro-
biological cultures (aerobic and anaerobic) are useful in 
the detection of pathogenic microorganisms causers of a 
secondary infection. Finally, you can take thomographic 
images to establish the extent of bone necrosis and for a 
more accurate diagnosis of the complications (maxillary 
sinusitis (figure 3), oro-nasal or oro-antral communication, 
pathologic fracture of mandible…).
In the case that you have to perform dental treatments, if  
they are non invasive they will not need to delay the begin-
ning of the Bps therapy. However, invasive dental procedures 
like tooth removals, root canal therapy and periodontal 
surgery force the start of Bps therapy to be deferred by at 
least one month and require prophylactic antibiotic cove-
rage with penicillin (for individuals with a penicillin allergy, 
combination therapy using quinolones and metronidazol 
should be employed because clindamycin alone does not 
cover either Actynomices or Eikenella corrodens, microor-
ganisms that frequently colonize exposed bone) (1). In our 
hands it is necessary to support an attitude as conservative 
as possible, performing removal of semiinclude and nonres-
torable tooth and functional rehabilitation of those that are 
restorable. According to other reports, rooth canal therapy 
and amputation of the crown is better than extraction in 
nonrestorable tooth. (14).
An exam of the prosthesis would be suitable to confirm 
correct adjustment and to remove them at night, teaching 
the patient about good dental hygiene and performing 
systematic reviews of the oral cavity every 3 or 4 months 
(hard and soft tissues) by the oncologist to notify the oral 
and maxillofacial surgeon every symptom.
In patients with established ONJ, intermittent or continous 
antibiotic together with minimal surgical debridements 
can be beneficial to palliate this kind of injuries. The goal 
of the treatment is to prevent a secondary infection in the 
soft tissues and an osteomyelitis and therefore to prevent 
the pain. Good dental hygiene and the use of mouth rinses 
and clorohexidina gels are almost as important (15). So far 
the duration of the antibiotic treatment and the beneficial 
effects of the antiseptical mouth rinses have not been defined 
although relief  of the pain and control of the progression 
of  the exposed bone have been seen. The antibiotic of 
choice is still penicillin. With regard to antiseptic mouth 
rinses gluconate of clorohexidina at 0.12% (Peridex®) or 
periodontal bags of clorohidrate of minocicline (Arestín®) 
could be used.
Sometimes you can choose minimal surgical debridements 
and regulate the acute edge of the exposed bone and closure 
with mucous flaps although it does not ensure the absence 
of new exposed bone, the recurrence of osteonecrosis or of 
the osteomyelitis. Instead of this removable devices, similar 
to prosthesis, can be used to cover the exposed bone. Also 
correct adjustment of dentures and their removal at night 
are important to reduce irritation and traumatism on the 
soft tissues.
Interruption of Bps therapy is a controversial issue. Due to 
its molecular structure (analogue to pirofosfates), Bps are 
accumulated in high levels inside the bone matrix, therefore, 
although we interrupt Bps therapy they stay in the organism 
for a long time. On the other hand, cessation of Bps therapy 
can produce worse consequences, like hypercalcemy asso-
ciated with tumour or skeletal complications in metastatic 
cancer. The oncologist, who is in charge of the treatment, 
will decide discontinuation of the therapy in collaboration 
with an oral and maxillofacial surgeon or other specialist. 
Hyperbaric oxygen has no proven efficiency and therefore 
is not recommended.
E271
Med Oral Patol Oral Cir Bucal 2007;12:E267-71.                                                                                                                                                                                   Osteonecrosis of the jaws and bisphosphonates Med Oral Patol Oral Cir Bucal 2007;                                                               12:E267-71.                                                                                                                                                                                  Osteonecrosis of the jaws and bisphosphonates
Any dental care not strictly necessary wouldn´t be perfor-
med with Bps therapy and always under the authorization 
of the oncologist. Therefore osteointegrated implants and 
any invasive dental treatment related to aesthetic dental 
would be contraindicated.
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